09:27 AM EDT, 09/17/2025 (MT Newswires) -- Cingulate ( CING ) said Wednesday it signed a commercial supply agreement with Bend Bio Sciences to manufacture CTx-1301, a drug candidate for attention-deficit/hyperactivity disorder, or ADHD.

Under the agreement, Bend Bio Sciences will exclusively manufacture CTx-1301 in the US through 2028 and Cingulate ( CING ) will purchase 100% of the US supply, subject to US Food and Drug Administration approval, the company said.

Cingulate ( CING ) said it filed a new drug application with the US Food and Drug Administration for CTx-1301 on July 31.

Shares of Cingulate ( CING ) fell more than 2% in recent premarket activity Wednesday.